Please wait a minute...
文章检索
预防医学  2026, Vol. 38 Issue (6): 588-592    DOI: 10.19485/j.cnki.issn2096-5087.2026.06.011
  论著 本期目录 | 过刊浏览 | 高级检索 |
健康体检人群前列腺特异性抗原灰区协同回访管理效果评价
邵银燕, 周河燃, 邓雪雨
杭州市中医院,浙江 杭州 310007
Effect of collaborative follow-up management for prostate-specific antigen gray zone among individuals undergoing physical examinations
SHAO Yinyan, ZHOU Heran, DENG Xueyu
Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 310007, China
全文: PDF(793 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 评价“泌尿外科专科医生-健康管理中心专员”协同回访管理对健康体检人群中前列腺特异性抗原(PSA)灰区者的干预效果。方法 选择2022—2024年在杭州市中医院健康管理中心接受健康体检且首次血清PSA检测结果为4.0~10.0 ng/mL的体检者为研究对象。2022年1月—2023年12月检出的PSA灰区体检者纳入对照组,实施常规管理;2024年1—12月检出的PSA灰区体检者纳入干预组,实施协同回访管理。通过杭州市中医院健康管理中心体检信息系统及检验系统、随访登记记录收集基本信息、随访信息、复诊情况和诊疗结局记录等;采用《前列腺癌认知度调查问卷》调查前列腺癌相关知识认知水平。比较两组随访可及性、复诊依从性和前列腺癌病理确诊比例,采用重复测量资料的方差分析比较两组前列腺癌相关知识得分干预前后差异。结果 纳入对照组2 188人,干预组1 294人;两组婚姻状况、吸烟、高血压、糖尿病、前列腺增生、慢性前列腺炎、前列腺癌家族史和首次检测PSA水平比较,差异无统计学意义(均P>0.05)。干预组随访可及性、复诊依从性分别为96.68%、91.19%,高于对照组的88.03%、37.52%(均P<0.05)。干预组可追溯诊疗结局记录获取率、病理确诊前列腺癌比例分别为89.88%、12.21%,高于对照组的35.37%和9.04%(均P<0.05)。重复测量资料的方差分析结果显示,前列腺癌相关知识得分的组间与时间交互效应有统计学意义(P<0.05),干预组干预前后前列腺癌相关知识得分上升幅度为4.53分,大于对照组的2.05分。结论 协同回访管理可提高体检人群PSA灰区者的复诊依从性和诊疗结局记录完整性,提高前列腺癌相关知识认知水平,并有助于前列腺癌早发现。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
邵银燕
周河燃
邓雪雨
关键词 前列腺特异性抗原前列腺癌随访管理    
AbstractObjective To evaluate the intervention effect of collaborative follow-up management by urological specialists and health management center coordinators on individuals with prostate-specific antigen (PSA) in the gray zone undergoing physical examinations. Methods Participants who underwent physical examinations at the Health Management Center of Hangzhou Hospital of Traditional Chinese Medicine from 2022 to 2024 and had initial serum PSA levels of 4.0-10.0 ng/mL were enrolled as study subjects. Examinees with PSA in the gray zone identified from January 2022 to December 2023 were assigned to the control group and received routine management, while those identified from January to December 2024 were assigned to the intervention group and received collaborative follow-up management. Basic information, follow-up data, re-examination records and treatment outcomes were collected through the Health Management Center's examination information system, laboratory system, and follow-up registration records of the Hangzhou Hospital of Traditional Chinese Medicine. The prostate cancer-related knowledge was assessed using the Prostate Cancer Awareness Questionnaire. The follow-up accessibility, re-examination adherence, and pathological diagnosis rate of prostate cancer were compared between the two groups. The differences in prostate cancer knowledge scores between the two groups before and after intervention were compared using repeated-measures analysis of variance. Results There were 2 188 participants in the control group and 1 294 participants in the intervention group. No significant differences were found between the two groups in marital status, smoking, hypertension, diabetes mellitus, benign prostatic hyperplasia, chronic prostatitis, family history of prostate cancer and initial PSA level (all P>0.05). The follow-up accessibility and re-examination adherence in the intervention group were higher than in the control group (96.68% vs. 88.03%, 91.19% vs. 37.52%, both P<0.05). The acquisition rate of traceable treatment outcome records and pathological diagnosis rate of prostate cancer were higher than in the control group (89.88% vs. 35.37%, 12.21% vs. 9.04%, both P<0.05). Repeated-measures analysis of variance revealed a significant interaction effect between group and time for prostate cancer knowledge scores (P<0.05). The increase in scores from baseline to post-intervention was 4.53 points in the intervention group, which was greater than the 2.05 points observed in the control group. Conclusion Collaborative follow-up management can improve re-examination adherence and the completeness of treatment outcome records among examinees with PSA in the gray zone, enhance prostate cancer-related knowledge, and facilitate early detection of prostate cancer.
Key wordsprostate-specific antigen    prostate cancer    follow-up management
收稿日期: 2025-12-18      修回日期: 2026-05-05     
中图分类号:  R193.3  
基金资助:浙江省卫生健康行业科技计划项目(2025HY0741)
作者简介: 邵银燕,本科,副主任护师,主要从事健康管理工作,E-mail:2332872856@qq.com
引用本文:   
邵银燕, 周河燃, 邓雪雨. 健康体检人群前列腺特异性抗原灰区协同回访管理效果评价[J]. 预防医学, 2026, 38(6): 588-592.
SHAO Yinyan, ZHOU Heran, DENG Xueyu. Effect of collaborative follow-up management for prostate-specific antigen gray zone among individuals undergoing physical examinations. Preventive Medicine, 2026, 38(6): 588-592.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2026.06.011      或      https://www.zjyfyxzz.com/CN/Y2026/V38/I6/588
[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 李星,曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究,2021,48(1):98-102.
[3] 邹浩然,范医东,吕仁广.超声引导下经会阴与经直肠途径前列腺穿刺的临床应用效果对比[J].山东第一医科大学(山东省医学科学院)学报,2022,43(3):205-208.
[4] 杜丽娜,张遵浩,管梦娇,等.新型FP-Growth模型在预测PSA为4~10 ng/mL的前列腺癌中应用研究[J].中国男科学杂志,2025,39(2):45-51.
[5] 赫捷,陈万青,李霓,等.中国前列腺癌筛查与早诊早治指南(2022,北京)[J].中华肿瘤杂志,2022,44(1):29-53.
[6] 中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组.前列腺癌筛查中国专家共识(2021年版)[J].中国癌症杂志,2021,31(5):435-440.
[7] WEI J T,BAROCAS D,CARLSSON S,et al.Early detection of prostate cancer:AUA/SUO guideline part I:prostate cancer screening:erratum[J/OL].J Urol,2025,214(1)[2026-05-05].http://doi.org/10.1097/JU.0000000000004546.
[8] 陶逸然,余佳倩,蒋聿瑛,等.基于PSA的前列腺癌筛查临床特征与分层干预研究:单中心经验[J].临床泌尿外科杂志,2025,40(6):529-534.
[9] 罗志强,黄建文,曹乃龙,等.基于PI-RADS v2评分在PSA 4~10 ng/mL患者前列腺癌预测模型的构建及验证[J].临床泌尿外科杂志,2022,37(2):109-113,118.
[10] 毕新刚. 前列腺癌PSA筛查国内外研究进展[J].中国现代医药杂志,2023,25(12):1-8.
[11] 陈可欣,陈万青,黄育北,等.常见恶性肿瘤联合筛查专家共识(2025版)[J].中国肿瘤临床,2025,52(14):703-726.
[12] 秦晓健,顾成元,黄永强,等.基于卫生经济学评价的我国前列腺癌筛查项目策略优化研究[J].中国卫生经济,2021,40(6):9-13.
[1] 陈梦倩, 王小红, 周凡, 张小兰, 徐则林. 2016—2024年金华市前列腺癌发病和死亡趋势分析[J]. 预防医学, 2025, 37(10): 1035-1038.
[2] 章群, 王永, 陈洁平, 包凯芳, 冯玥溢, 王小丽. 2011—2023年宁波市前列腺癌发病和死亡趋势分析[J]. 预防医学, 2025, 37(1): 46-50.
[3] 赵俊峰, 何丽华, 李为翊, 邹亚伟, 陈博, 牛欣, 高淑娜. 2002—2019年黄浦区前列腺癌发病和死亡趋势[J]. 预防医学, 2024, 36(10): 878-881,886.
[4] 秦敏晔, 邱晶, 王洵之, 赵丽霞, 陆艳. 2006—2022年张家港市60岁及以上居民前列腺癌疾病负担分析[J]. 预防医学, 2023, 35(12): 1080-1083, 1088.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed